DIUXF (Diaceutics) YoY EBITDA Growth: 80.36% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DIUXF Diaceutics PLC DIUXF
80 GF Score
Price $2.00
GF Value $2.07
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Diaceutics YoY EBITDA Growth?

Diaceutics DIUXF 80 YoY EBITDA Growth is 80.36% as of Dec. 2025. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.07 (Fairly Valued). The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Diaceutics's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 80.36%.

Diaceutics's EBITDA per Share for the six months ended in Dec. 2025 was $0.10.

Diaceutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Diaceutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diaceutics YoY EBITDA Growth Chart

Diaceutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,133.33 40.54 -30.77 16.67 130.95

Diaceutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.00 0.00 55.56 64.29 80.36
DIUXF
80GF Score
Diaceutics PLC DIUXF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diaceutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Diaceutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.097-0.042)/ | 0.042 |
=130.95 %

Diaceutics's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.101-0.056)/ | 0.056 |
=80.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 80.36% mean?
Diaceutics (DIUXF) has a YoY EBITDA Growth of 80.36% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Diaceutics and its competitors.
Is Diaceutics' YoY EBITDA Growth too high?
Diaceutics' current YoY EBITDA Growth is 80.36%. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' YoY EBITDA Growth compare to VEEV and BTSG?
Diaceutics' YoY EBITDA Growth of 80.36% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Diaceutics and its competitors. Diaceutics's current YoY EBITDA Growth is 80.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.07, compared to a current price of $2.00 — trading 3.4% below its estimated fair value. The current YoY EBITDA Growth is 80.36%. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Diaceutics (DIUXF), the current YoY EBITDA Growth is 80.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diaceutics (DIUXF) Overvalued in 2026?

Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued. The current stock price of $2.00 is trading 3.4% below its estimated GF Value™ of $2.07. GuruFocus considers Diaceutics to be Fairly Valued.

Key valuation signals for DIUXF:

  • YoY EBITDA Growth: 80.36%
  • GF Value™: $2.07 vs. price of $2.00 (3.4% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diaceutics Business Description

Other Exchanges DXRX:UK7DC:Germany
Address Dataworks at Kings Hall Health & Wellbeing Park, First Floor, Building Two, County Antrim, Belfast, GBR, BT9 6GW
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score

Get the complete analysis for DIUXF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price
$2.07
GF Value